Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy

September 17, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search